Heparin-Induced Thrombocytopenia Management

Risk Assessment and Monitoring

The American College of Chest Physicians recommends assessing the risk of HIT before initiating heparin therapy, with patients having a >1% risk requiring platelet count monitoring every 2-3 days from day 4 to day 14 of therapy 1
Patients with a <1% risk of HIT do not require routine platelet count monitoring, as per the American College of Chest Physicians guidelines 1
Monitoring for clinical signs of HIT, including unexplained thrombocytopenia, venous or arterial thrombosis, skin lesions, or acute systemic reactions after IV heparin bolus, is crucial, according to the American College of Chest Physicians 3

The American College of Chest Physicians recommends immediately discontinuing all forms of heparin when HIT is suspected, and initiating alternative nonheparin anticoagulation even before laboratory confirmation due to the high thrombotic risk 1, 4
Performing laboratory testing for HIT antibodies to confirm diagnosis is essential, as stated by the American College of Chest Physicians 3

The American College of Chest Physicians suggests using argatroban, lepirudin, or danaparoid as first-line therapy for patients with normal renal function 1, 3
For patients requiring urgent cardiac surgery, the American College of Chest Physicians recommends using bivalirudin if surgery cannot be delayed 5
For patients requiring percutaneous coronary intervention, the American College of Chest Physicians suggests using bivalirudin (Grade 2B) or argatroban (Grade 2C) 1

The American College of Chest Physicians advises against starting VKA until platelets have substantially recovered (usually to at least 150 × 10^9/L) 1
When starting VKA, the American College of Chest Physicians recommends using low initial doses (maximum 5 mg warfarin or 6 mg phenprocoumon) 1
Overlapping VKA with a nonheparin anticoagulant for a minimum of 5 days and until the INR is within target range is recommended by the American College of Chest Physicians 1

The American College of Chest Physicians suggests that for severe thrombocytopenia, platelet transfusions should only be given if bleeding occurs or during invasive procedures with high bleeding risk 1
For patients with a history of HIT requiring anticoagulation, the Anaesthesia society prefers oral anticoagulants (VKA or DOACs) or fondaparinux 6
Providing patients with a medical card documenting their HIT history and laboratory test results is recommended by the Anaesthesia society 6

The Anaesthesia society recommends limiting heparin exposure to the shortest possible duration (<4-5 days) 6
Considering using oral anticoagulants or LMWH instead of unfractionated heparin when possible is suggested by the Anaesthesia society 6
Prescribing heparin only for validated indications is advised by the Anaesthesia society 6